CRL

Business Profile & Competitive Position

Charles River Laboratories International, Inc. is classified in the Healthcare sector and the Medical – Diagnostics & Research industry. Operationally, it describes itself as a full-service, non-clinical global drug-development partner. Its work spans research model technologies, discovery and safety assessment services (both GLP and non-GLP), and manufacturing-support products and services. Revenue flows through three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. For 2025, total revenue was $4.0 billion, with DSA contributing 59.8%, RMS 21.1%, and Manufacturing 19.1% of the total.

The company’s footprint is broad: more than 120 sites across more than 20 countries. That geographic and service diversification is structurally relevant, because contract research and non-clinical development are high-touch, regulated businesses where clients often prefer integrated partners. However, the most recent margin figures do not show a currently healthy moat in earnings terms. Net margin is negative 6.0%, and return on equity is negative 7.7%. Those numbers imply that scale and market-leading positioning have not, at this stage, translated into positive net profitability or shareholder returns. The competitive story is therefore about breadth and integration potential rather than demonstrated pricing power or capital efficiency right now.

Financial Posture

As of the current snapshot, Charles River Laboratories carries a market capitalization of $14.8 billion and trades at a P/E of −63.3. The negative P/E is a direct consequence of the negative net margin: the company is losing money on a trailing basis, so the multiple reflects the market’s valuation of a turnaround rather than a normalized earnings stream. The net margin of −6.0% and ROE of −7.7% confirm that profitability and capital returns are both underwater in the most recent reporting window.

The stock’s beta is 1.41, meaning it has exhibited materially higher volatility than the overall market. That is consistent with a business tied to biopharma spending cycles, M&A-driven client demand, and operational restructuring. With the price at $306.36, an RSI of 65.0, and the 50-day exponential moving average at $273.22, the shares are closer to recent highs relative to that moving-average level. None of these figures alone indicate value or overvaluation, but they do frame CRL as a higher-beta, turnaround-style healthcare services name rather than a stable, defensive cash-flow compounder.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines a clear operational agenda over the next few years. A central priority is footprint optimization: Charles River intends to close or consolidate approximately 12 additional sites over the next two years, principally within DSA and RMS. That aligns with the margin pressure described above and suggests management is using rationalization rather than pure expansion to repair returns.

Organizationally, the company plans to integrate Discovery Services and Safety Assessment into one DSA organization with a combined sales force and leadership structure. The stated objective is to become “the scientific partner of choice” by offering a comprehensive, integrated portfolio that can accelerate biomedical research and therapeutic innovation. Another priority is expanding Biologics Testing Solutions service offerings and facilities in the U.S. and Europe. In January 2026, the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That move is consistent with vertical integration around research-model supply. The 2030 plan referenced in recent headlines—5%–7% growth and $300 million in savings—fits the same theme: fewer sites, more integrated services, and cost-based profitability improvement.

Macro & Geopolitical Exposure

Because Charles River operates in the Medical – Diagnostics & Research industry, its macro exposures are those common to global contract research organizations and providers of research models. Regulatory exposure is substantial: GLP and non-GLP safety studies must meet FDA, EMA, and other national standards, and any tightening of animal-welfare or import rules can affect the supply and use of research models, especially non-human primates. Trade policy and tariffs matter because the company sources and ships biological materials and laboratory products across borders; disruptions raise input costs or delay studies. Currency risk is relevant because approximately 120 sites operate across more than 20 countries, so revenue and costs are denominated in multiple currencies. Finally, biopharma R&D spending is cyclical and sensitive to capital-market conditions; softness in biotech funding or big-pharma budget conservatism can reduce demand for discovery and safety-assessment services.

Recent Developments

Several headlines from late September 2026 capture the current narrative. On September 24, businesswire.com reported that Charles River highlighted a “refreshed strategic vision to drive profitable growth and long-term value creation” at its 2026 Investor Day. The same day, Seeking Alpha published the CRL Analyst/Investor Day transcript, giving investors direct access to management’s messaging. On September 25, marketbeat.com reported that Charles River is targeting 5%–7% growth and $300 million in savings under its 2030 plan. Then on September 30, defenseworld.net noted that analysts had a consensus price target of $290.00 for the stock. At the current snapshot price of $306.36, the shares sit modestly above that consensus target, a relationship that simply reflects where the market is currently pricing the company relative to sell-side estimates.

Earnings Behavior & Post-Earnings Drift

Charles River has produced an unusually consistent earnings record over the last eight reported quarters, beating estimates in all eight, for a 100% beat rate with an average earnings surprise of 9.3%. That is a strong headline streak, but the post-earnings price action has been mixed and demonstrates that a beat does not guarantee a positive short-term move.

The average five-day price move after earnings across those eight quarters is 1.24%, classified as an upward drift. Recent quarter-by-quarter results show real divergence. For the August 5, 2026 report, CRL delivered $3.02 versus a $2.74 estimate, a 10.2% surprise; the stock rose 1.84% the next day and 9.07% over the following five sessions. In contrast, the May 7, 2026 quarter produced $2.06 against $1.96, a 5.1% beat, but the stock fell 2.23% the next day and 12.42% over the next five days. The February 18, 2026 report showed $2.39 versus $2.33 (2.6% surprise) with a next-day gain of 3.95% and a five-day gain of 6.05%. The November 5, 2025 report delivered $2.43 against $2.32 (4.7% surprise), with the stock up 1.9% the next session and 2.27% over the next five sessions.

The next scheduled report is November 4, 2026, before the market opens, with a consensus EPS estimate of $2.97. Traders and analysts watching this report should note that while the beat rate is perfect, the post-report drift has been volatile, especially over the five-day window, suggesting that forward guidance, margin commentary, and strategic-plan updates may weigh as heavily as the headline EPS number.

For readers who want to go deeper into how institutions are positioning around these earnings dynamics and the full analyst verdict, the complete institutional research view is worth reviewing alongside the raw financial figures.